New antibody aimed at ARDS shows promise in early trial
Disease control
Ongoing
This study tests a single dose of an antibody called ALT-100 in people with moderate to severe acute respiratory distress syndrome (ARDS), a life-threatening lung condition. The trial involves 15 hospitalized adults and compares the drug to a placebo. The main goal is to check sa…
Phase: PHASE2 • Sponsor: Aqualung Therapeutics Corp. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC